ACRV — Acrivon Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1781174 ·
Last close
$1.43
Market Cap
$61.28M
52W High
$3.56
52W Low
$1.27
ADV30
220,277
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -18,518,000 | -17,897,000 | 85,748,000 | 47,535,000 | 14,974,000 |
| Jun 2026 | 0 | — | -18,668,000 | -17,964,000 | 99,092,000 | 41,417,000 | 12,427,000 |
| Mar 2026 | 0 | — | -19,902,000 | -19,042,000 | 107,832,000 | 34,064,000 | 12,317,000 |
| Dec 2025 | 0 | — | -20,116,000 | -18,985,000 | 129,717,000 | 41,499,000 | 17,201,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-62,920,000
Investing CF
$55,509,000
Financing CF
$6,927,000
CapEx
$-1,219,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.94
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-311,887,000
Inventory
—
Receivables
—
ST Investments
$48,542,000
EBIT TTM
$-78,373,000
Pretax Income TTM
$-74,225,000
Interest Exp TTM
—
Analysts
6
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -84,114,000 | -77,905,000 | 129,717,000 | 17,201,000 | 112,516,000 | -63,665,000 |
| Dec 2024 | 0 | -89,199,000 | -80,556,000 | 196,588,000 | 19,802,000 | 176,786,000 | -65,669,000 |
| Dec 2023 | 0 | -67,103,000 | -60,388,000 | 138,265,000 | 17,070,000 | 121,195,000 | -42,641,000 |
| Dec 2022 | 0 | -32,657,000 | -31,167,000 | 181,226,000 | 10,751,000 | 170,475,000 | -30,117,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-74,225,000
OpCashFlow TTM
—
Assets (Latest)
$99,092,000
Forward EPS
$-1.69
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| FBIO | Fortress Biotech, Inc. | $60.70M | $1.82 | — |
| KZIA | KAZIA THERAPEUTICS LTD | $60.68M | $5.31 | — |
| LFVN | Lifevantage Corp | $60.62M | $4.78 | — |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | $62.03M | $3.01 | — |
| RANI | Rani Therapeutics Holdings, Inc. | $64.61M | $0.56 | — |
News headlines (Yahoo Finance, 1h cache)
Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCθ Inhibitor Preclinical Program from Aqilion AB
2026-11-06 13:00 · Yahoo
Acrivon to Present Late-Breaking Oral Plenary Presentation and Posters at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
2026-11-04 21:30 · Yahoo
Acrivon Announces Late-Breaking Oral Plenary Presentation of Early Phase 1/2 Clinical Results in AP3-Predicted Tumors for its First-in-Class WEE1/PKMYT1 Inhibitor ACR-2316 at the 38th EORTC-NCI-AACR S
2026-10-29 12:00 · Yahoo
Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027
2026-10-20 12:30 · Yahoo
What Makes Acrivon Therapeutics, Inc. (ACRV) a New Buy Stock
2026-09-15 16:00 · Yahoo
Acrivon Therapeutics, Inc. (ACRV) Just Flashed Golden Cross Signal: Do You Buy?
2026-09-03 13:55 · Yahoo
Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference
2026-09-02 12:00 · Yahoo
Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer
2026-08-31 12:30 · Yahoo
Here's Why Acrivon Therapeutics, Inc. (ACRV) is a Great Momentum Stock to Buy
2026-08-24 16:00 · Yahoo
Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference
2026-07-21 20:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.